1guidance for the work-up and diagnosis of spatially limited NMO spectrum disorders is provided by the task force
2the task force suggests concepts for treatment of acute exacerbations and attack prevention based on expert opinion.
3that further clinical and histopathological studies changed the concept and place of NMO within the expanding range of autoimmune disorders of the CNS
4The period for eligible articles ranged from 1965 to September 2009, and following suggestions from the reviewers also individual articles beyond this period
5NMO primarily affects non-whites and populations with a minor European contribution to their genetic composition
6Predictors of a recurrent course were a longer interattack interval between the first two clinical episodes,older age at onset, female gender and less severe motor impairment at the sentinel myelitis event
lilimailfish
2010-10-27 22:06
nmo ？I do not known
xunlei
2010-10-28 21:18
引用
引用第1楼lilimailfish于2010-10-27 22:06发表的 : nmo ？I do not known
7Repeated NMO attacks are the main cause of accumulation of neurological impairment, whereas permanent disability in MS is primarily a feature of secondary progression
8A history of other autoimmune diseases, higher attack frequency during the first 2 years of disease and better motor recovery following the index myelitis event were associated with increased risk of fatality in recurrent NMO
9However, normal appearances or shorter lesions can be found very early during relapse or in residual atrophic stage
10In a study on LETM relapses in NMO
xunlei
2010-11-13 21:13
11fluoroimmunoprecipitation assays
12A French study using IIF did not report differences with regard to age and onset of disease,
13presence of NMO-IgG was associated with a worse course
14Detection of NMO-IgG was also associated with a higher probability for >3 periventricular lesions and localization within the deep white matter
15 at the nadir of exacerbations
16A French NMO study reported that the presence of NMO-IgG was linked to HLA-DRB1*01*03 (majority DR3)
17AQP4 antibodies in spatially limited syndromes
18 importantly appear to predict outcome in terms of conversion to NMO
19 In a series of three rapidly recurring LETM patients, AQP4 antibodies could not be detected in serum, but in CSF (class IV), confirming the diagnosis of a spatially limited NMO spectrum disorder and mandating initiation of immunosuppressive treatment
20All major criteria are required, but may be separated by an unspecified interval
21Non-specific brain T2-signal abnormalities not satisfying the Barkhof criteria for dissemination in space used in the revised McDonald criteria
22‘linear’ periventricular/corpus callosum signal abnormality, but not ovoid, not extending into the parenchyma of the cerebral hemispheres in Dawson finger configuration.
